Three-Dimensional Melted Electrowriting Drug Coating Fibers for the Prevention of Device-Associated Infections: A Pilot Study.
Joana P MartinsMaria Elisabete Teixeira da SilvaAntónio A FernandesSofia Costa de OliveiraPublished in: Bioengineering (Basel, Switzerland) (2024)
Medical device-related infections (DRIs), especially prevalent among critically ill patients, impose significant health and economic burdens and are mainly caused by bacteria. Severe infections often necessitate device removal when antibiotic therapy is inefficient, delaying recovery. To tackle this issue, PCL drug-eluting coated meshes were explored, and they were printed via melt electrowriting (MEW). These meshes were coated with gentamicin sulfate (GS) and tetracycline hydrochloride (TCH) and underwent FTIR analysis to confirm drug integration. Antimicrobial activity was assessed via agar diffusion assays and biofilm formation assays against bacterial strains: Pseudomonas aeruginosa ATCC 27853, Escherichia coli ATCC 25922, Staphylococcus aureus ATCC 43300, and Staphylococcus epidermidis ATCC 35984. FTIR analysis evidenced the presence of the drugs in the meshes. TCH displayed broad-spectrum antimicrobial activity against all strains, whereas GS was effective against all except S. aureus . These findings indicate the potential of cost-effective ultra-fine drug coating fibers for medical device applications, offering infection prevention during implantation. This preliminary study demonstrates the feasibility of producing drug-eluting fibers for DRI prevention through a non-toxic, fast, and cost-efficient technique, paving the way for enhanced patient care and reduced healthcare costs.
Keyphrases
- biofilm formation
- escherichia coli
- pseudomonas aeruginosa
- staphylococcus aureus
- healthcare
- candida albicans
- cystic fibrosis
- drug induced
- public health
- emergency department
- mental health
- methicillin resistant staphylococcus aureus
- acinetobacter baumannii
- high throughput
- bone marrow
- adverse drug
- mass spectrometry
- electronic health record
- drug resistant
- human health
- climate change
- cell therapy
- low cost
- risk assessment